ARA-290 vs BPC-157 | Research Comparison | QSC Peptides
ARA-290 vs BPC-157: Research Comparison
Mechanism, research applications, and key differences
Quick Comparison
Factor
ARA-290
BPC-157
Primary Target
Innate Repair Receptor (IRR)
See BPC-157 hub
Origin
EPO helix B surface peptide
Distinct origin
Key Research
Phase 2: small fibre neuropathy, metabolic repair
See BPC-157 hub
Detailed Comparison
ARA-290 (Cibinetide) targets the innate repair receptor (IRR/EpoR) for neuroprotection and metabolic repair. BPC-157 acts via NOS/VEGF pathways for tissue healing. Both show anti-inflammatory activity but via distinct receptors — ARA-290 is more CNS/metabolic focused, BPC-157 more tissue/GI focused.
Which to Choose for Your Research?
The choice depends on your primary research target. ARA-290 is the right tool when the research question involves IRR-mediated cytoprotection — neuropathy models, sarcoidosis inflammation, or metabolic beta cell protection. BPC-157 suits different primary targets. For comprehensive cytoprotection research, some protocols combine both compounds targeting complementary pathways.
